- In April 2024, PhytoHealth Corporation, a Taiwan-based biopharmaceutical company, initiated a Phase II clinical trial for its botanical drug PHY906, derived from a traditional Chinese herbal formulation. The trial targets advanced pancreatic cancer and aims to evaluate the drug’s efficacy in reducing chemotherapy-induced toxicity. This development highlights PhytoHealth’s commitment to advancing evidence-based botanical oncology therapies and integrating traditional knowledge with modern clinical research to address unmet needs in cancer treatment
- In March 2024, Indena S.p.A., an Italian leader in botanical active ingredient development, announced a strategic partnership with a U.S.-based oncology research center to co-develop a new botanical extract targeting triple-negative breast cancer. The collaboration focuses on leveraging Indena’s expertise in phytochemistry and sustainable sourcing to develop clinically validated botanical formulations for aggressive cancer types. This marks a significant step in bridging scientific innovation and natural compound-based oncology research
- In February 2024, Himalaya Wellness Company, a global player in herbal healthcare, launched CystCare Botanica, an adjunct botanical therapy designed to support ovarian cancer treatment. Developed in collaboration with Indian oncology institutions, the formulation is based on Ayurvedic principles and supported by preclinical data. This reflects a growing trend of blending traditional medicine with modern oncological applications and promoting regional innovation in botanical therapeutics
- In January 2024, Avesthagen Limited, a genomics and botanical drug development company in India, received regulatory clearance to begin clinical trials of its botanical drug AV-D8 for colorectal cancer. The drug, derived from a proprietary blend of Indian medicinal plants, aims to provide anti-inflammatory and tumor-inhibiting benefits. This milestone showcases the increasing regulatory support for botanical oncology drug development in emerging markets
- In December 2023, Kampo Research Inc., based in Japan, expanded its research initiative with leading universities to study the efficacy of traditional Kampo herbal medicines in post-chemotherapy recovery. The project aims to standardize formulations and validate their use in managing side effects such as fatigue, nausea, and immunosuppression. This underscores the continued integration of culturally significant botanical remedies into modern oncology protocols and Japan’s proactive approach to personalized, patient-centric cancer care
